Which has higher earnings and valuation, PDSB or FBRX?

Forte Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A Forte Biosciences N/A N/A -$69.38M -$4.64 N/A

Is PDSB or FBRX more profitable?

Forte Biosciences' return on equity of -106.17% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets PDS Biotechnology N/A -346.02% -102.36% Forte Biosciences N/A -106.17% -85.50%

Which has higher earnings and valuation, NERV or PDSB?

PDS Biotechnology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Minerva Neurosciences N/A N/A -$293.42M -$29.16 N/A PDS Biotechnology N/A N/A -$34.50M -$0.67 N/A

Is NERV or PDSB more profitable?

Minerva Neurosciences' return on equity of 0.00% beat PDS Biotechnology's return on equity. Company Net Margins Return on Equity Return on Assets Minerva Neurosciences N/A N/A -32.63% PDS Biotechnology N/A -346.02% -102.36%

PDS Biotechnology (PDSB) Competitors

$1.06 +0.03 (+2.91%)

Closing price 04:00 PM Eastern

Extended Trading

$1.06 +0.00 (+0.47%)

As of 05:58 PM Eastern

Compare

PDSB vs. ACIU, SLGL, FBRX, LENZ, and NERV

Should you buy PDS Biotechnology stock or one of its competitors? MarketBeat compares PDS Biotechnology with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with PDS Biotechnology include AC Immune (ACIU), Sol-Gel Technologies (SLGL), Forte Biosciences (FBRX), LENZ Therapeutics (LENZ), and Minerva Neurosciences (NERV). These companies are all part of the "pharmaceutical products" industry.

How does PDS Biotechnology compare to AC Immune?

PDS Biotechnology (NASDAQ:PDSB) and AC Immune (NASDAQ:ACIU) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, media sentiment, earnings, analyst recommendations, risk, institutional ownership and dividends.

In the previous week, PDS Biotechnology and PDS Biotechnology both had 1 articles in the media. PDS Biotechnology's average media sentiment score of 1.87 beat AC Immune's score of 1.45 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
AC Immune	Positive

PDS Biotechnology presently has a consensus price target of $9.00, suggesting a potential upside of 749.06%. AC Immune has a consensus price target of $7.50, suggesting a potential upside of 253.77%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, equities research analysts clearly believe PDS Biotechnology is more favorable than AC Immune.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
AC Immune	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

26.8% of PDS Biotechnology shares are held by institutional investors. Comparatively, 51.4% of AC Immune shares are held by institutional investors. 9.2% of PDS Biotechnology shares are held by insiders. Comparatively, 4.6% of AC Immune shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

PDS Biotechnology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, AC Immune has a beta of 1.59, meaning that its share price is 59% more volatile than the broader market.

PDS Biotechnology has a net margin of 0.00% compared to AC Immune's net margin of -1,788.02%. AC Immune's return on equity of -125.26% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
AC Immune	-1,788.02%	-125.26%	-40.85%

PDS Biotechnology has higher earnings, but lower revenue than AC Immune. AC Immune is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
AC Immune	$4.31M	50.06	-$85.03M	-$0.82	N/A

Summary

PDS Biotechnology beats AC Immune on 8 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to Sol-Gel Technologies?

PDS Biotechnology (NASDAQ:PDSB) and Sol-Gel Technologies (NASDAQ:SLGL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, risk, earnings, profitability, media sentiment and institutional ownership.

In the previous week, Sol-Gel Technologies had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Sol-Gel Technologies and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Sol-Gel Technologies' score of -0.67 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
Sol-Gel Technologies	Negative

PDS Biotechnology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market. Comparatively, Sol-Gel Technologies has a beta of 1.13, meaning that its share price is 13% more volatile than the broader market.

Sol-Gel Technologies has higher revenue and earnings than PDS Biotechnology. Sol-Gel Technologies is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Sol-Gel Technologies	$19.39M	10.65	-$6.13M	-$0.34	N/A

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 26.2% of Sol-Gel Technologies shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 66.5% of Sol-Gel Technologies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

PDS Biotechnology presently has a consensus target price of $9.00, suggesting a potential upside of 749.06%. Sol-Gel Technologies has a consensus target price of $110.00, suggesting a potential upside of 49.66%. Given PDS Biotechnology's higher possible upside, equities analysts clearly believe PDS Biotechnology is more favorable than Sol-Gel Technologies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Sol-Gel Technologies	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.60

PDS Biotechnology has a net margin of 0.00% compared to Sol-Gel Technologies' net margin of -5.66%. Sol-Gel Technologies' return on equity of -3.17% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Sol-Gel Technologies	-5.66%	-3.17%	-2.58%

Summary

Sol-Gel Technologies beats PDS Biotechnology on 9 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Forte Biosciences?

PDS Biotechnology (NASDAQ:PDSB) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Forte Biosciences is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
Forte Biosciences	N/A	N/A	-$69.38M	-$4.64	N/A

PDS Biotechnology currently has a consensus price target of $9.00, indicating a potential upside of 749.06%. Forte Biosciences has a consensus price target of $67.00, indicating a potential upside of 298.34%. Given PDS Biotechnology's higher possible upside, research analysts plainly believe PDS Biotechnology is more favorable than Forte Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Forte Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.50

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by company insiders. Comparatively, 4.4% of Forte Biosciences shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Forte Biosciences' return on equity of -106.17% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
Forte Biosciences	N/A	-106.17%	-85.50%

In the previous week, Forte Biosciences had 1 more articles in the media than PDS Biotechnology. MarketBeat recorded 2 mentions for Forte Biosciences and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat Forte Biosciences' score of 0.93 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
Forte Biosciences	Positive

PDS Biotechnology has a beta of 1.57, suggesting that its share price is 57% more volatile than the broader market. Comparatively, Forte Biosciences has a beta of 2.87, suggesting that its share price is 187% more volatile than the broader market.

Summary

Forte Biosciences beats PDS Biotechnology on 7 of the 13 factors compared between the two stocks.

How does PDS Biotechnology compare to LENZ Therapeutics?

PDS Biotechnology (NASDAQ:PDSB) and LENZ Therapeutics (NASDAQ:LENZ) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

PDS Biotechnology has higher earnings, but lower revenue than LENZ Therapeutics. LENZ Therapeutics is trading at a lower price-to-earnings ratio than PDS Biotechnology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A
LENZ Therapeutics	$19.09M	10.81	-$82.13M	-$3.60	N/A

PDS Biotechnology has a beta of 1.57, meaning that its stock price is 57% more volatile than the broader market. Comparatively, LENZ Therapeutics has a beta of 0.58, meaning that its stock price is 42% less volatile than the broader market.

PDS Biotechnology has a net margin of 0.00% compared to LENZ Therapeutics' net margin of -519.30%. LENZ Therapeutics' return on equity of -46.82% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
PDS Biotechnology	N/A	-346.02%	-102.36%
LENZ Therapeutics	-519.30%	-46.82%	-43.32%

In the previous week, LENZ Therapeutics had 5 more articles in the media than PDS Biotechnology. MarketBeat recorded 6 mentions for LENZ Therapeutics and 1 mentions for PDS Biotechnology. PDS Biotechnology's average media sentiment score of 1.87 beat LENZ Therapeutics' score of 0.90 indicating that PDS Biotechnology is being referred to more favorably in the media.

Company	Overall Sentiment
PDS Biotechnology	Very Positive
LENZ Therapeutics	Positive

PDS Biotechnology currently has a consensus target price of $9.00, suggesting a potential upside of 749.06%. LENZ Therapeutics has a consensus target price of $29.80, suggesting a potential upside of 352.89%. Given PDS Biotechnology's higher probable upside, research analysts clearly believe PDS Biotechnology is more favorable than LENZ Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
LENZ Therapeutics	1 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.50

26.8% of PDS Biotechnology shares are owned by institutional investors. Comparatively, 54.3% of LENZ Therapeutics shares are owned by institutional investors. 9.2% of PDS Biotechnology shares are owned by insiders. Comparatively, 8.3% of LENZ Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

PDS Biotechnology beats LENZ Therapeutics on 8 of the 15 factors compared between the two stocks.

How does PDS Biotechnology compare to Minerva Neurosciences?

Minerva Neurosciences (NASDAQ:NERV) and PDS Biotechnology (NASDAQ:PDSB) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their valuation, media sentiment, earnings, analyst recommendations, institutional ownership, risk, profitability and dividends.

In the previous week, Minerva Neurosciences and Minerva Neurosciences both had 1 articles in the media. Minerva Neurosciences' average media sentiment score of 1.87 equaled PDS Biotechnology'saverage media sentiment score.

Company	Overall Sentiment
Minerva Neurosciences	Very Positive
PDS Biotechnology	Very Positive

34.6% of Minerva Neurosciences shares are owned by institutional investors. Comparatively, 26.8% of PDS Biotechnology shares are owned by institutional investors. 1.7% of Minerva Neurosciences shares are owned by insiders. Comparatively, 9.2% of PDS Biotechnology shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

PDS Biotechnology is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Minerva Neurosciences	N/A	N/A	-$293.42M	-$29.16	N/A
PDS Biotechnology	N/A	N/A	-$34.50M	-$0.67	N/A

Minerva Neurosciences has a beta of -0.18, meaning that its share price is 118% less volatile than the broader market. Comparatively, PDS Biotechnology has a beta of 1.57, meaning that its share price is 57% more volatile than the broader market.

Minerva Neurosciences' return on equity of 0.00% beat PDS Biotechnology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Minerva Neurosciences	N/A	N/A	-32.63%
PDS Biotechnology	N/A	-346.02%	-102.36%

Minerva Neurosciences presently has a consensus target price of $10.50, indicating a potential upside of 124.84%. PDS Biotechnology has a consensus target price of $9.00, indicating a potential upside of 749.06%. Given PDS Biotechnology's stronger consensus rating and higher possible upside, analysts plainly believe PDS Biotechnology is more favorable than Minerva Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Minerva Neurosciences	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
PDS Biotechnology	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33

Summary

PDS Biotechnology beats Minerva Neurosciences on 7 of the 11 factors compared between the two stocks.

Get PDS Biotechnology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PDSB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PDSB vs. The Competition

Export

Metric	PDS Biotechnology	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$59.17M	$3.28B	$6.43B	$11.71B
Dividend Yield	N/A	2.33%	2.67%	5.55%
P/E Ratio	-1.58	18.99	24.49	23.62
Price / Sales	N/A	290.48	500.49	105.27
Price / Cash	N/A	118.24	42.36	56.09
Price / Book	5.89	8.00	10.43	6.70
Net Income	-$34.50M	$23.89M	$3.56B	$337.26M
7 Day Performance	-1.85%	-3.49%	-1.38%	-1.41%
1 Month Performance	-15.20%	1.02%	0.86%	1.15%
1 Year Performance	-36.90%	34.39%	19.43%	22.61%

PDS Biotechnology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PDSB PDS Biotechnology	3.5283 of 5 stars	$1.06 +2.9%	$9.00 +749.1%	-39.8%	$59.17M	N/A	N/A	20
ACIU AC Immune	2.918 of 5 stars	$2.20 +0.6%	$7.50 +240.4%	+7.6%	$223.39M	$4.31M	N/A	140	Positive News
SLGL Sol-Gel Technologies	2.7568 of 5 stars	$79.35 -0.8%	$110.00 +38.6%	+978.1%	$222.41M	$19.39M	N/A	50	Short Interest Increase
FBRX Forte Biosciences	1.8978 of 5 stars	$16.07 +2.5%	$67.00 +317.0%	+42.3%	$222.23M	N/A	N/A	5	News Coverage
LENZ LENZ Therapeutics	3.7883 of 5 stars	$6.97 +3.6%	$29.80 +327.9%	-78.3%	$217.94M	$20.99M	N/A	110

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PDSB) was last updated on 6/10/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

PDS Biotechnology (PDSB) Competitors

PDSB vs. ACIU, SLGL, FBRX, LENZ, and NERV

How does PDS Biotechnology compare to AC Immune?

Summary

How does PDS Biotechnology compare to Sol-Gel Technologies?

Summary

How does PDS Biotechnology compare to Forte Biosciences?

Summary

How does PDS Biotechnology compare to LENZ Therapeutics?

Summary

How does PDS Biotechnology compare to Minerva Neurosciences?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

PDS Biotechnology (PDSB) Competitors

PDSB vs. ACIU, SLGL, FBRX, LENZ, and NERV

How does PDS Biotechnology compare to AC Immune?

Does the media prefer PDSB or ACIU?

Do analysts rate PDSB or ACIU?

Do insiders & institutionals hold more shares of PDSB or ACIU?

Which has more volatility & risk, PDSB or ACIU?

Is PDSB or ACIU more profitable?

Which has preferable valuation & earnings, PDSB or ACIU?

Summary

How does PDS Biotechnology compare to Sol-Gel Technologies?

Does the media prefer PDSB or SLGL?

Which has more risk and volatility, PDSB or SLGL?

Which has stronger valuation and earnings, PDSB or SLGL?

Do insiders and institutionals hold more shares of PDSB or SLGL?

Do analysts recommend PDSB or SLGL?

Is PDSB or SLGL more profitable?

Summary

How does PDS Biotechnology compare to Forte Biosciences?

Which has higher earnings and valuation, PDSB or FBRX?

Do analysts recommend PDSB or FBRX?

Do institutionals & insiders believe in PDSB or FBRX?

Is PDSB or FBRX more profitable?

Does the media prefer PDSB or FBRX?

Which has more risk and volatility, PDSB or FBRX?

Summary

How does PDS Biotechnology compare to LENZ Therapeutics?

Which has preferable earnings & valuation, PDSB or LENZ?

Which has more volatility and risk, PDSB or LENZ?

Is PDSB or LENZ more profitable?

Does the media refer more to PDSB or LENZ?

Do analysts rate PDSB or LENZ?

Do insiders and institutionals hold more shares of PDSB or LENZ?

Summary

How does PDS Biotechnology compare to Minerva Neurosciences?

Does the media prefer NERV or PDSB?

Do insiders & institutionals have more ownership in NERV or PDSB?

Which has higher earnings and valuation, NERV or PDSB?

Which has more volatility and risk, NERV or PDSB?

Is NERV or PDSB more profitable?

Do analysts prefer NERV or PDSB?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB vs. The Competition

PDS Biotechnology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools